UCB SA (UCB)
Euronext
Closed
Aug 24, 2026
Day's Range
219.1052 wk Range
191.20Overview - UCB - UCB SA
Key Statistics
Valuation
Enterprise Value
45.09B
P/E (Trailing)
‪19.56‬
P/E (Forward)
‪15.91‬
PEG Ratio
‪15.91‬
Price / Sales (TTM)
‪4.95‬
EV / EBITDA
‪13.49‬
Profitability
Profit Margin
‪25.73%‬
Operating Margin
‪33.32%‬
Return on Assets
‪8.97%‬
Return on Equity
‪20.56%‬
Ownership
Shares Outstanding
190.66M
Float
120.15M
Held by Insiders
‪36.27%‬
Held by Institutions
‪38.55%‬
Price stats
Beta
‪0.18‬
50-Day Avg
‪239.60‬
200-Day Avg
‪247.95‬
Dividends
Payout Ratio
‪12.81%‬
Frequency
Annual
Analyst Consensus
20 analysts
Average price target
‪€ 285.26‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - UCB - UCB SA
Peers - UCB - UCB SA
Peer Comparison
Compared with companies in Biotechnology listed on Euronext.
Profile Summary - UCB - UCB SA
About
UCB SA is a multinational biopharmaceutical company headquartered in Brussels, Belgium, founded in 1928 by Emmanuel Janssen. It specializes in developing innovative medicines for severe neurological and immunological diseases, including epilepsy, Parkinson's disease, Crohn's disease, psoriasis, and autoimmune…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
